These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 16377135)
1. Obtaining pediatric indications for new anti-epileptic drugs: how and when. Garofalo E Epilepsy Res; 2006 Jan; 68(1):38-42. PubMed ID: 16377135 [TBL] [Abstract][Full Text] [Related]
2. When to start drug treatment for childhood epilepsy: the clinical-epidemiological evidence. Arts WF; Geerts AT Eur J Paediatr Neurol; 2009 Mar; 13(2):93-101. PubMed ID: 18567515 [TBL] [Abstract][Full Text] [Related]
3. Monotherapy in children and infants. Wilfong AA Neurology; 2007 Dec; 69(24 Suppl 3):S17-22. PubMed ID: 18071153 [TBL] [Abstract][Full Text] [Related]
4. Changing requirements for evaluation of pharmacologic agents. Chesney RW; Christensen ML Pediatrics; 2004 Apr; 113(4 Suppl):1128-32. PubMed ID: 15060209 [TBL] [Abstract][Full Text] [Related]
5. Criteria supporting the study of drugs in the newborn. Ward RM; Benitz WE; Benjamin DK; Blackmon L; Giacoia GP; Hudak M; Lasky T; Rodriguez W; Selen A Clin Ther; 2006 Sep; 28(9):1385-98. PubMed ID: 17062311 [TBL] [Abstract][Full Text] [Related]
6. Guidelines for new antiepileptic drug evaluation. Hixson JD; French JA Rev Neurol Dis; 2004; 1 Suppl 1():S18-26. PubMed ID: 16400291 [TBL] [Abstract][Full Text] [Related]
7. Antiepileptic drug development program. Porter RJ Prog Clin Biol Res; 1983; 127():53-66. PubMed ID: 6351101 [TBL] [Abstract][Full Text] [Related]
8. Clinical development of antiepileptic drugs for children. Garofalo E Neurotherapeutics; 2007 Jan; 4(1):70-4. PubMed ID: 17199017 [TBL] [Abstract][Full Text] [Related]
9. The economics of pediatric formulation development for off-patent drugs. Milne CP; Bruss JB Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801 [TBL] [Abstract][Full Text] [Related]
10. [Are children getting the right drugs?]. Bratlid D Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857 [TBL] [Abstract][Full Text] [Related]
11. The evolution of legislation to regulate pediatric clinical trials: Present and continuing challenges. Gans-Brangs KR; Plourde PV Adv Drug Deliv Rev; 2006 Apr; 58(1):106-15. PubMed ID: 16530291 [TBL] [Abstract][Full Text] [Related]
17. Stimulation programs for pediatric drug research--do children really benefit? Boots I; Sukhai RN; Klein RH; Holl RA; Wit JM; Cohen AF; Burggraaf J Eur J Pediatr; 2007 Aug; 166(8):849-55. PubMed ID: 17225950 [TBL] [Abstract][Full Text] [Related]
18. Issues in the design of clinical trials for safety in HIV-infected children. Lindsey JC; Kline MW Pediatr AIDS HIV Infect; 1996 Apr; 7(2):69-82. PubMed ID: 11361484 [TBL] [Abstract][Full Text] [Related]
19. Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe. Porter RJ; Baulac M; Nohria V Epilepsy Res; 2010 May; 89(2-3):163-75. PubMed ID: 20347575 [TBL] [Abstract][Full Text] [Related]
20. Considerations in the treatment of a first unprovoked seizure. Haut SR; Shinnar S Semin Neurol; 2008 Jul; 28(3):289-96. PubMed ID: 18777475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]